Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11802MR)

This product GTTS-WQ11802MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11802MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12674MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ10547MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ9529MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ1586MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ12963MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ5341MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ3212MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW